119 results
Page 3 of 6
8-K
EX-10.1
40xyedhfw3q oyzlw
26 Oct 21
EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline
7:00am
8-K
EX-2.1
cuitd3ud3
26 Oct 21
EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline
7:00am
D
ns0ulps ywd
23 Aug 21
$10.75M in options / securities to be acquired, sold $10.75M, 14 investors
4:15pm
424B5
p9g1o
11 Aug 21
Prospectus supplement for primary offering
6:56am
8-K
EX-10.1
etv y3ric9d
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-10.2
k9c dxd7c53jhi5soew8
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
ar681rji
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-10.1
khw0nw m0bh
26 Jul 21
EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer
4:18pm
8-K/A
EX-99.1
w9ycrw2beo
5 Mar 21
Financial Statements and Exhibits
4:15pm
8-K
EX-10.1
wf8t5canbcysxa pptd
1 Feb 21
Departure of Directors or Certain Officers
6:55am
8-K
EX-10.3
kknyji1k7ypcjiqshgt
1 Feb 21
Departure of Directors or Certain Officers
6:55am
D
zj0ahifqvd r3impwue6
21 Jan 21
$8M in equity / options / securities to be acquired, sold $8M, 1 investor
4:15pm
8-K
EX-10.2
eynbxh6esjvapl
6 Jan 21
EyeGate Enters Into Agreement for $8.0 Million Private Placement
6:55am
8-K
EX-10.1
dvh uwjx5y0p
6 Jan 21
EyeGate Enters Into Agreement for $8.0 Million Private Placement
6:55am
D
d6yq n0x6vgsaixwxd
4 Jan 21
Indefinite amount in equity, sold $3.2M, 15 investors
12:00am
8-K
EX-10.1
xj0ogz096pmmk6ej
21 Dec 20
EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma
6:55am
8-K
EX-2.1
od1dwua iyti70mcx
21 Dec 20
EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma
6:55am